The US FDA wants to ensure that its promised series of guidances on patient input are drafted with a new target audience in mind: patient advocates who may be new to the regulatory process.
That point was driven home during a Dec. 18 public workshop ahead of the release of the first draft guidance in the planned series of four over the next five years
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?